Strategic Performance and Market Dynamics
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.
Record gross margins of 41.5% were driven by a favorable shift toward diversified end markets, which now represent 59% of total revenue.
The medical segment achieved 45% year-over-year growth, fueled by broad-based demand for sensing and actuation technologies in advanced diagnostics and therapeutics.
Industrial markets extended a recovery trend with 16% growth, supported by secular tailwinds in automation, digitalization, and energy efficiency.
Transportation sales declined 2% as the company navigates a cautious global light vehicle production environment impacted by tariffs and geopolitical uncertainties.
Management is pivoting from being a component supplier to providing high-value integrated subsystems in aerospace and defense to capture more value from government funding flows.
Operational execution and the ‘Evolution 2030’ strategy remain the primary frameworks for converting diversified growth into higher-quality earnings.
Outlook and Strategic Assumptions
Full-year 2026 guidance was raised to $565-$585 million in sales, assuming continued momentum in diversified markets despite flat-to-down light vehicle production.
Aerospace and defense revenue is expected to strengthen in the second half of 2026 as government funding deployments accelerate for key programs.
The commercial vehicle market is projected to see modest growth driven by freight fundamental improvements and pre-buy activity ahead of 2027 emissions regulations.
Management expects medical therapeutics volumes to normalize in the second half of the year following a period of rapid capacity expansion.
The company is maintaining a cautious stance on transportation due to ongoing tariff developments and potential cost pressures from precious metal inflation.
Non-Recurring Factors and Risk Callouts
Second quarter EPS included a $0.07 favorable impact from unusual items, specifically foreign currency favorability and a large customer reimbursement for R&D.
A record $100 million sensor award was secured with a North American OEM, highlighting the success of powertrain-agnostic product strategies.
Management is actively monitoring Section 301 tariff changes and USMCA negotiations to ensure cost-neutral outcomes through customer and supplier collaborations.
The company continues to manage a competitive transition in the commercial vehicle space as a major customer, Cummins, integrates a second source into their supply base.
